Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

105.06 +2.43 (+2.37%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
65 66 Next >
While growth is established for NYSE:NVO, the stock's valuation remains reasonable.
NYSE:NVO is showing decent growth, but is still valued reasonably. 
Via Chartmill
Weight Watchers gains from Oprah’s GLP-1 weight-loss
Oprah Winfrey revealed she has lost over 60 pounds and is on the path to reaching her weight goal of 167 lbs. She credits this to taking GLP-1 medication 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
2024’s Power Players: 7 Stocks Racing to a Trillion Valuation
Whether in 2024, or in the years ahead, each of these seven stocks could become the next trillion dollar companies. 
Via InvestorPlace
Prediction: These 3 Stocks Will Soar in 2024
Investors could enjoy an especially happy new year with these great stocks. 
Via The Motley Fool
3 Ken Griffin Stocks to Invest Like Citadel
Invest like Citadel founder and billionaire Ken Griffin with these stocks that have strong potential heading into 2024. 
Via InvestorPlace
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Via Benzinga
(NVO) - Analyzing Novo Nordisk's Short Interest
Via Benzinga
Here's How Much $1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
Via Benzinga
These 3 Companies Can Be the Next Stock-Split Stocks in 2024
Since mid-2021, Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk have conducted stock splits. Three well-known companies look set to follow in... 
Via The Motley Fool
Meet the Stock-Split Stock Warren Buffett Is Likeliest to Buy in 2024
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a stock-split stock that checks all the right boxes for the Oracle of Omaha. 
Via The Motley Fool
3 Stock-Split Stocks Billionaires Are Piling Into Ahead of 2024
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three industry leaders Wall Street's brightest money managers want to own for... 
Via The Motley Fool
Novo Nordisk, Maker Of 'Miracle' Weight Loss Drug Ozempic, Announces Mega Factory In Dublin
Via Benzinga
Will Novo Nordisk Be Worth More Than Meta Platforms by 2030?
The gap in market cap between these two companies is big today, but it could shrink in the future. 
Via The Motley Fool
Fake Ozempic - FDA and Novo Nordisk Warn Against Counterfeit Ozempic Penetrating US Market Amid High Demand
The FDA on Thursday said it continues to investigate counterfeit Novo Nordisk A/S's&n 
Via Benzinga
Exposures Product Safety
7 Low-Volatility Stocks for Stable Growth in 2024
Wager on these stocks to buy for stable growth, handpicked for their low volatility and potential to weather economic headwinds. 
Via InvestorPlace
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
Which weight-loss stocks are good buys today? 
Via The Motley Fool
Looking to Invest in the Next Big Craze Like Ozempic? This 1 Emerging Field Could Be It.
Diabetes and weight-loss drugs won't be the hottest category of medicines forever. 
Via The Motley Fool
Why Novo Nordisk Stock Was Up on a Down Day for the Market
As if the company's top two products weren't popular enough, a new media report made them even more appealing. 
Via The Motley Fool
Weight Loss Drugs By Novo Nordisk, Eli Lilly Don't Deter Nestle's Coffee Demand - CEO Explains Why
Nestle S.A. (OTC: NSRGY) CEO Mark Schneider stated that despite the rising use of weight loss medications like Eli Lilly And Company's (NYSE: LLY) Zepbound and Novo Nordisk's  
Via Benzinga
These 2 Unstoppable Stocks Could Make You Richer in 2024 and Beyond
Eli Lilly and Novo Nordisk are disrupting the weight-loss market with treatments like Mounjaro and Ozempic. 
Via The Motley Fool
Novo Nordisk Collaborates With India's Online Marketplace To Remove Unauthorized Wegovy Listings
IndiaMART, an online marketplace in India, has reportedly taken action to remove unauthorized listings of Novo Nordisk A/S's (NYSE: NVO) highly sought-after weight-loss drug Wegovy after engaging in... 
Via Benzinga
LifeMD expands telehealth GLP-1weight-loss service with Medifast
LifeMD Inc. (NASDAQ: LFMD) is a direct-to-consumer (DTC) comprehensive virtual healthcare platform. The company offers per-visit and membership plan pricing 
Via MarketBeat
3 Stocks With the Potential to Be 2024’s Company of the Year
Finding the top stocks for 2024 is like looking for a needle in a haystack. Nonetheless, some of these names could be company of the year. 
Via InvestorPlace
Obesity/Diabetes Drug Class GLP-1s' Cost-Saving Potential: Decoding Impact on Healthcare Spending
Due to the recent achievements of GLP-1s, Goldman Sachs sees significant potential for Eli Lilly And Co (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), and other companies to venture 
Via Benzinga
Wegovy's Success Spurs Novo Nordisk Foundation's Philanthropic Initiative To Enhance Respiratory Disease Vaccines
The Novo Nordisk Foundation pledged 1.8 billion Danish crowns ($265 million) toward an initiative to enhance vaccines for respiratory illnesses.  
Via Benzinga
Why Novo Nordisk Stock Is Moving Higher Today
An Indian e-commerce company is helping Novo Nordisk combat illegal sales of weight loss drug Wegovy. 
Via The Motley Fool
Topics Law Enforcement
Exposures Legal
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
2024 is going to be a sizzler in the biopharma sector. 
Via The Motley Fool
As 2023 Comes To A Close And Updates Are Expected From Many Companies, Are These Three Unique Biotech Names On Your Watchlist?
Biotech stocks have had a tough run in 2023 so far. As of early November, the iShares Biotechnology ETF (IBB) was down 7.5% while the S&P 500 was up more than 14%. 
Via Benzinga
Topics ETFs
25% of Warren Buffett's Secret Portfolio Is Invested in These 3 ETFs. Here's Why They're Great Picks for 2024.
Buffett didn't personally pick these ETFs. But all three could make him money in the new year. 
Via The Motley Fool
Topics ETFs
3 Stock-Split Stocks With 51% to 128% Upside in 2024, According to Select Wall Street Analysts
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three high-flying stocks a trio of Wall Street analysts believe can soar in the... 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.